Accession Number: | 0001827672-23-000014 |
Date: | 2023-02-15 |
Issuer: | TARSUS PHARMACEUTICALS, INC. (TARS) |
Original Submission Date: |
AZAMIAN BOBAK R.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE, CA 92618
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-02-15 | S | 8,000 | d | $15.28 | 1,094,106 | indirect | ||
COMMON STOCK | 2023-02-15 | 0 | $0.00 | 1,750 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | the sales reported in this form 4 were effected by an automatic sale pursuant to a rule 10b5-1 trading plan adopted by the reporting person on june 14, 2022. |
f2 | the price reported in column 4 is a weighted average price. the shares were pooled and sold in multiple transactions at prices ranging from $15.03 to $15.40. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
f3 | the reporting person is the trustee of the bobak azamian living trust, established april 16, 2018 and has voting and dispositive power with respect to these shares. |